XCUR News and Press, Exicure Inc. From 05/19/23

2023-05-19 16:23:49 ET Exicure ( NASDAQ: XCUR ) said Friday it received a notice of non-compliance from Nasdaq for not filing its form 10-Q for the quarterly period ended March 31, 2023 on time. The company said is working diligently to complete its form 10-Q and intends to fi...

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely fil...

2023-05-04 16:58:14 ET Exicure ( NASDAQ: XCUR ) has invested in Cyworld Z, the operator of the Korean SNS platform "Cyworld," the company said on Thursday. The company has purchased $1 million convertible bonds issued by Cyworld Z as part of the investment. The company sai...

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it has invested in Cyworld Z Co. Ltd. (“Cyworld Z”), the operator of a Korean SNS p...

2023-04-27 07:26:49 ET Exicure ( NASDAQ: XCUR ) names Jung-Sang (Michael) Kim as CEO and CFO of the company and a Class II director of the company’s board of directors. Mr. Kim succeeds Dr. Matthias Schroff, who yesterday stepped down as CEO and a Cla...

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer...

2023-04-14 07:01:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nano-cap penny stocks are arguably the most volatile and speculative investments you can make other than nano-cap cryptos. Shares of these small businesses generally have a market capital...

2023-03-27 17:25:30 ET Exicure press release ( NASDAQ: XCUR ): FY GAAP EPS of -$0.56. Revenue of $28.83M. Shares -3.54% AH. For further details see: Exicure GAAP EPS of -$0.56, revenue of $28.83M

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the year ended December 31, 2022 and provided an update on its business strategy ...

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. (“CBI ...